Ewan Pearson is Professor of Diabetic Medicine at the University of Dundee, Visiting Professor at the University of Edinburgh, and Honorary Consultant in Diabetes and Endocrinology at Ninewells Hospital and Medical School in Dundee. In the School of Medicine, he is the Head of Division, Population Health & Genomics, and the Director of the Dundee Clinical Academic Track.
Professor Pearson obtained his medical degree from the University of Cambridge School of Clinical Medicine, UK. He undertook a Wellcome Trust Clinical Training fellowship with Prof Andrew Hattersley at the University of Exeter Medical School, UK and completed his PhD in the physiology and treatment of monogenic diabetes. He then moved to Dundee where he was supported by a Chief Scientist Office Clinician Scientisit fellowship and, more recently, by a Wellcome Trust Investigator Award. Over the last ten years in Dundee his research interests have been in the phenotypic and genotypic determinants of drug response in diabetes, and in stratified approaches to the management of diabetes. He leads the IMI-DIRECT project on stratification in type 2 diabetes and is strand 2 lead on the ABPI-MRC funded MASTERMIND project. Ewan has been awarded the Royal College of Physicians of Edinburgh Croom Lecture, an EASD Rising Star award, the Diabetes UK RD Lawrence Lecture and the EASD Minkowski Award for his work in these areas.
'The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project' Life Sciences, Society and Policy, vol. 14, no. 1. DOI:
'Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register' Diabetes Care, vol. 41, no. 9, pp. 2010-2018. DOI:
'Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes' Diabetes, vol. 67, no. 7, pp. 1428-1440. DOI:
'The search for predictive metabolic biomarkers for incident T2DM' Nature Reviews Endocrinology. DOI:
'Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study' The Lancet Diabetes and Endocrinology. DOI:
'Pharmacogenetics and target identification in diabetes' Current Opinion in Genetics & Development, vol. 50, pp. 68-73. DOI:
'Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study' Diabetologia, vol. 61, no. 6, pp. 1344-1353. DOI:
'Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (Go DARTS)' International Journal of Epidemiology, vol. 47, no. 2, pp. 380-381j. DOI:
'Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference' Nature Communications, vol. 9, 711, pp. 1-11. DOI:
'Pharmacokinetics of metformin in patients with gastrointestinal intolerance' Diabetes, Obesity & Metabolism. DOI:
'Characteristics of people with high visit-to-visit glycaemic variability in Type 2 diabetes' Diabetic Medicine, vol. 35, no. 2, pp. 262-267. DOI:
'Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study' PLo S ONE, vol. 13, no. 1, e0189886, pp. 1-19. DOI:
'Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study' Diabetologia, vol. 61, no. 1, pp. 117-129. DOI:
'Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-Term Glycemic Response to DPP-4 Inhibitor Therapy' Diabetes Care, vol. 41, no. 4, pp. 705-712. DOI:
'Quantitative MRI evaluation of whole abdomen adipose tissue volumes in healthy volunteers-validation of technique and implications for clinical studies' British Journal of Radiology, vol. 91, no. 1087, 20180025. DOI:
'A common missense variant of LILRB5 is associated with statin intolerance and myalgia' European Heart Journal, vol. 38, no. 48, pp. 3569-3575. DOI:
'Rates of glycaemic deterioration in a real-world population with type 2 diabetes' Diabetologia. DOI:
'Clarifying the relationship between metformin, acute kidney injury and lactic acidosis' Nature Reviews Nephrology, vol. 14, 70. DOI:
'Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes' Diabetologia, vol. 60, no. 11, pp. 2231-2239. DOI:
'Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a Genetics of Diabetes Audit and Research Tayside study' Pharmacogenetics and Genomics, vol. 27, no. 10, pp. 356-362. DOI:
'Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study' Diabetes Therapy, vol. 8, no. 5, pp. 1031-1045. DOI:
'The mechanisms of action of metformin' Diabetologia, vol. 60, no. 9, pp. 1577-1585. DOI:
'Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A Go DARTS Study' Diabetes, Obesity & Metabolism. DOI:
'Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients' Diabetes Care, vol. 40, no. 8, pp. 1017-1025. DOI:
'CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia' Circulation: Cardiovascular Genetics, vol. 10, no. 4, e001737 . DOI:
'A Genome-Wide Association Study of IVGTT-Based Measures of First Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants' Diabetes, vol. 66, no. 8, pp. 2296-2309. DOI:
'Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A Go Darts study' Diabetes, Obesity & Metabolism, vol. 19, no. 11, pp. 1579-1586. DOI:
'Quantifying the extent to which index event biases influence large genetic association studies' Human Molecular Genetics, vol. 26, no. 5, pp. 1018-1030. DOI:
'Variants in pharmacokinetic transporters and glycemic response to metformin: A metgen meta-analysis' Clinical Pharmacology & Therapeutics, vol. 101, no. 6, pp. 763-772. DOI:
'The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes' Diabetes, Obesity & Metabolism, vol. 19, no. 3, pp. 356-363. DOI:
'Predicting glycated hemoglobin levels in the non-diabetic general population: Development and validation of the DIRECT-DETECT prediction model - a DIRECT study' PLo S ONE, vol. 12, no. 2, e0171816, pp. 1-13. DOI:
'Defining drug response for stratified medicine' Drug Discovery Today, vol. 22, no. 1, pp. 173-179. DOI:
'Statistical power considerations in genotype-based recall randomized controlled trials' Scientific Reports, vol. 6, 37307, pp. 1-11. DOI:
'Effect of Serotonin Transporter 5HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A Go DARTS Study' Diabetes Care, vol. 39, no. 11, pp. 1896-1901. DOI:
'CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes.' Diabetes Care, vol. 39, no. 11, pp. 1902-1908. DOI:
'Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes' Diabetes Care, vol. 39, no. 11, pp. 1879-1888. DOI:
't RNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy' Diabetic Medicine, vol. 33, no. 9, pp. e21-e25. DOI:
'Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin' Nature Genetics, vol. 48, no. 9, pp. 1055-1059. DOI:
'Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension and heart disease' Diabetes, vol. 65, no. 8, pp. 2448-2460. DOI:
'Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design' Cardiovascular Diabetology, vol. 15, 97, pp. 1-11. DOI:
'Personalized medicine in diabetes: The role of 'omics' and biomarkers' Diabetic Medicine, vol. 33, no. 6, pp. 712-717. DOI:
'Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery' Nature Reviews Endocrinology, vol. 12, no. 6, pp. 337-346. DOI:
'Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach' Practical Diabetes, vol. 33, no. 4, pp. 115-117. DOI:
Pharmacogenetics of sulfonylureas. in JC Florez (ed.), The Genetics of Type 2 Diabetes and Related Traits: Biology, Physiology and Translation. pp. 483-497. DOI:
'Pharmacogenetics in type 2 diabetes: Influence on response to oral hypoglycemic agents' Pharmacogenomics and Personalized Medicine, vol. 9, pp. 17-29. DOI:
'Should studies of diabetes treatment stratification correct for baseline Hb A1c?' PLo S ONE, vol. 11, no. 4, e0152428. DOI:
'Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes' Diabetic Medicine, vol. 33, no. 4, 13040, pp. 511-514. DOI:
'Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance' Diabetic Medicine, vol. 33, no. 3, pp. 371-375. DOI:
'Metformin and the gastrointestinal tract' Diabetologia, vol. 59, no. 3, pp. 426-435. DOI:
'Adherence to oral glucose-lowering therapies and associations with 1-year Hb A1c: A retrospective cohort analysis in a large primary care database' Diabetes Care, vol. 39, no. 2, pp. 258-263. DOI:
'Dissecting the etiology of type 2 diabetes in the Pima Indian population' Diabetes, vol. 64, no. 12, pp. 3993-3995. DOI:
'A common missense variant of LILRB5 is associated with statin intolerance: A Go DARTS study' 65th American Society of Human Genetics Annual Meeting, Baltimore, United States, 6/10/15 - 10/10/15, .
'Association of organic cation transporter 1 with intolerance to metformin in Type 2 diabetes: a Go DARTS study' Diabetes, vol. 64, no. 5, pp. 1786-1793. DOI:
'Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors' Diabetes Care, vol. 38, no. 2, pp. 323-328. DOI:
'Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium' Diabetologia, vol. 57, no. 6, pp. 1132-1142. DOI:
'Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis' The Lancet: Diabetes and Endocrinology, vol. 2, no. 6, pp. 481-487. DOI:
'RD Lawrence Lecture 2013: Stratified approaches to the management of diabetes' Diabetic Medicine, vol. 31, no. 4, pp. 393-398. DOI:
'Zinc transport and diabetes risk' Nature Genetics, vol. 46, no. 4, pp. 323-4. DOI:
'Clinical and genetic determinants of progression of type 2 diabetes: A DIRECT Study' Diabetes Care, vol. 37, no. 3, pp. 718-724. DOI:
'Genetics of Drug Response in Diabetes' Frontiers in Diabetes, vol. 23, pp. 158-172. DOI:
'Glycemic exposure and blood pressure influencing progression and remission of diabetic retinopathy: a longitudinal cohort study in Go DARTS' Diabetes Care, vol. 36, no. 12, pp. 3979-3984. DOI:
'An interesting case of new-onset ketosis-prone diabetes in a Scottish teaching hospital' British Journal of Diabetes and Vascular Disease, vol. 13, no. 5-6, pp. 265-268. DOI:
'Molecular mechanism of action of metformin: old or new insights?' Diabetologia, vol. 56, no. 9, pp. 1898-1906. DOI:
'Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects' Diabetes Care, vol. 36, no. 5, pp. 1413-1421. DOI:
'Is thiazolidinedione treatment an important cause of oedema?' Diabetic Medicine, vol. 30, no. Suppl. 1, P562, pp. 197-197. DOI:
'Clinical predictors of rate of progression of type 2 diabetes: an extreme case-control study' Diabetic Medicine, vol. 30, no. Suppl. 1, P213, pp. 94-94. DOI:
'Measuring endogenous insulin secretion in type 1 diabetes is life changing' Diabetic Medicine, vol. 30, no. Suppl. 1, P215, pp. 94-95. DOI:
'Metformin pharmacogenetics and SLC2A2: genome-wide association study and 2-stage replication in Go DARTS and UKPDS' Diabetic Medicine, vol. 30, no. Suppl. 1, P79, pp. 52-52. DOI:
'Insights from genome-wide association studies of drug response' Annual Review of Pharmacology and Toxicology, vol. 53, pp. 299-310. DOI:
'Is thiazolidinedione treatment an important cause of oedema?' Diabetes UK Professional Conference 2013, Manchester, United Kingdom, 13/03/13 - 15/03/13, .
'Clinical predictors of rate of progression of type 2 diabetes: an extreme case-control study' Diabetes UK Professional Conference 2013, Manchester, United Kingdom, 13/03/13 - 15/03/13, .
'Measuring endogenous insulin secretion in type 1 diabetes is life changing' Diabetes UK Professional Conference 2013, Manchester, United Kingdom, 13/03/13 - 15/03/13, .
'Metformin pharmacogenetics and SLC2A2: genome-wide association study and 2-stage replication in Go DARTS and UKPDS' Diabetes UK Professional Conference 2013, Manchester, United Kingdom, 13/03/13 - 15/03/13, .
'The first prospective study of treatment change in transcription factor maturity onset diabetes of the young (MODY): impact on glycaemic control and quality of life' Diabetic Medicine, vol. 30, no. Supplement 1, A69 (P434), pp. 25. DOI:
'Time to reconsider? Reassessment of diagnosis in long duration Type 1 diabetes with urinary C-peptide creatinine ratio and antibodies identifies people with alternate diagnoses' Diabetic Medicine, vol. 30, no. Supplement 1, A72 (P110), pp. 26-26. DOI:
'The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway' Diabetes. DOI:
'Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment' Pharmacogenetics and Genomics, vol. 23, no. 10, pp. 518-525. DOI:
'The utility of retinal screening in gestational diabetes' Diabetic Medicine, vol. 30, no. 8, pp. 1009-1010. DOI:
'Pharmacogenetics of oral antidiabetic drugs' International Journal of Endocrinology, vol. 2013, 686315. DOI:
'Common variants at 12q15 and 12q24 are associated with infant head circumference' Nature Genetics, vol. 44, no. 5, pp. 532-538. DOI:
'Common variants at 6q22 and 17q21 are associated with intracranial volume' Nature Genetics, vol. 44, no. 5, pp. 539-544. DOI:
'The role of ATM in response to metformin treatment and activation of AMPK reply' Nature Genetics, vol. 44, no. 4, pp. 361-362. DOI:
'A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts' Diabetologia, vol. 55, no. 7, pp. 1971-1977. DOI:
'Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes' Clinica Chimica Acta, vol. 413, no. 9-10, pp. 927-932. DOI:
'Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant' PLo S ONE, vol. 7, no. 6, e39362. DOI:
'Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis' Diabetic Medicine, vol. 29, no. 8, pp. e142-e150. DOI:
'Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs' Diabetologia, vol. 55, no. 11, pp. 2929-2937. DOI:
'Treating type 2 diabetes in youth: a depressing picture' Journal of the Royal College of Physicians of Edinburgh, vol. 42, no. 3, pp. 228. DOI:
'Determinants of glycemic response to metformin: do the organic cation transporters hold the key?' Pharmacogenomics Journal, vol. 12, no. 5, pp. 707-708.
'OCT3 is a major determinant of metformin effect in skeletal muscle' Pharmacogenomics Journal, vol. 12, no. 5, pp. 708-709.
'More OCT1 variants in the Asian population' Pharmacogenomics Journal, vol. 12, no. 5, pp. 709-709.
'Casting the net wider: a comprehensive candidate gene study' Pharmacogenomics Journal, vol. 12, no. 5, pp. 710-711.
'Identifying a new role for OCT1 in pharmacogenetics' Pharmacogenomics Journal, vol. 12, no. 5, pp. 711-711.
'Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology' Biochemical Pharmacology, vol. 81, no. 4, pp. 471-477. DOI:
'Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A Go-DARTS study' Clinical Pharmacology & Therapeutics, vol. 89, no. 2, pp. 210-216. DOI:
'Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes' Nature Genetics, vol. 43, no. 2, pp. 117-120. DOI:
'Generation, validation and humanisation of a novel insulin resistant cell model' Biochemical Pharmacology, vol. 80, no. 7, pp. 1042-1049. DOI:
'Cyp2c8 variant reduce the therapeutic response to thiazolidinediones - a godarts study' Diabetologia, vol. 53, pp. S133-S133.
'PPARG, insulin resistance and metformin pharmacogenetics-A Go DARTS study' Diabetes, vol. 59, pp. A115-A115.
'Insulin resistance before and after parathyroidectomy in patients with primary hyperparathyroidism-a pilot study' Endocrine Research, vol. 35, no. 2, pp. 85-93. DOI:
The Croom Lecture - Royal College of Physicians of Edinburgh
Activity: Types of External academic engagement - Invited talk
ESPT meeting Catania, Sicilly
Activity: Invited talk
EASD Genetics Study Group, Leiden
Activity: Invited talk